Standout Papers

Nirsevimab for Prevention of Hospitalizations Due to RSV in Infants 2023 2026 2024146
  1. Nirsevimab for Prevention of Hospitalizations Due to RSV in Infants (2023)
    Simon B. Drysdale, Katrina Cathie et al. New England Journal of Medicine

Immediate Impact

6 from Science/Nature 77 standout
Sub-graph 1 of 21

Citing Papers

Effectiveness of nirsevimab immunoprophylaxis against respiratory syncytial virus-related outcomes in hospital and primary care settings: a retrospective cohort study in infants in Catalonia (Spain)
2024 Standout
Impact of nirsevimab prophylaxis on paediatric respiratory syncytial virus (RSV)-related hospitalisations during the initial 2023/24 season in Luxembourg
2024 Standout

Works of Simon Royal being referenced

Nirsevimab for Prevention of Hospitalizations Due to RSV in Infants
2023 Standout

Author Peers

Author Last Decade Papers Cites
Simon Royal 175 123 83 490 170 17 960
Balamurugan Tangiisuran 99 93 52 510 181 55 1.0k
Laurie L. Briceland 169 140 41 361 65 52 998
Ingebjørg Buajordet 219 64 42 257 149 17 815
Louise Mallet 86 87 46 523 66 49 1.2k
Balthasar L. Hug 204 77 35 251 87 40 872
H. J. M. Beijer 57 43 52 374 208 23 819
Sarah Rodgers 99 316 120 497 52 40 1.1k
A.W. Lenderink 52 62 139 446 164 20 1.2k
Emma Davies 125 56 23 447 428 22 1.0k
Angela B. Hoth 132 190 18 753 70 13 1.1k

All Works

Loading papers...

Rankless by CCL
2026